A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

NCT03316131 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Asymptomatic Hyperuricemia

Interventions

DRUG: Verinurad
DRUG: Febuxostat
DRUG: Dapagliflozin
OTHER: Dapagliflozin matched placebo

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]